Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma

Logo poskytovatele

Varování

Publikace nespadá pod Fakultu sportovních studií, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

PUCCI Perla LEE Liam C HAN Miaojun MATTHEWS Jamie D JAHANGIRI Leila SCHLEDERER Michaela MANNERS Eleanor SORBY-ADAMS Annabel KAGGIE Joshua TRIGG Ricky M STEEL Christopher HARE Lucy JAMES Emily R PROKOPH Nina DUCRAY Stephen P MERKEL Olaf RIFATBEGOVIC Firkret LUO Ji TASCHNER-MANDL Sabine KENNER Lukas BURKE G A Amos TURNER Suzanne Dawn

Rok publikování 2024
Druh Článek v odborném periodiku
Časopis / Zdroj Nature Communications
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://www.nature.com/articles/s41467-024-47771-x
Doi http://dx.doi.org/10.1038/s41467-024-47771-x
Klíčová slova NRAS; miR-1304-5p; farnesyltransferase inhibition; ALK-mutant neuroblastoma
Přiložené soubory
Popis Targeting Anaplastic lymphoma kinase (ALK) is a promising therapeutic strategy for aberrant ALK-expressing malignancies including neuroblastoma, but resistance to ALK tyrosine kinase inhibitors (ALK TKI) is a distinct possibility necessitating drug combination therapeutic approaches. Using high-throughput, genome-wide CRISPR-Cas9 knockout screens, we identify miR-1304-5p loss as a desensitizer to ALK TKIs in aberrant ALK-expressing neuroblastoma; inhibition of miR-1304-5p decreases, while mimics of this miRNA increase the sensitivity of neuroblastoma cells to ALK TKIs. We show that miR-1304-5p targets NRAS, decreasing cell viability via induction of apoptosis. It follows that the farnesyltransferase inhibitor (FTI) lonafarnib in addition to ALK TKIs act synergistically in neuroblastoma, inducing apoptosis in vitro. In particular, on combined treatment of neuroblastoma patient derived xenografts with an FTI and an ALK TKI complete regression of tumour growth is observed although tumours rapidly regrow on cessation of therapy. Overall, our data suggests that combined use of ALK TKIs and FTIs, constitutes a therapeutic approach to treat high risk neuroblastoma although prolonged therapy is likely required to prevent relapse.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info